13F Holdings
中文EN

GRCE Grace Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1444192 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-173.9%
TTM EPS YoY-118.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-36.2%
ROA-34.5%
ROIC (approx.)-46.7%
Asset turnover—

Leverage & solvency

Liabilities / assets3.8%
Debt / equity0.00x
Current ratio13.61x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.42x
Accruals ratio-20.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31
Income statement
Revenue————$100.00M
Cost of revenue————$0
Gross profit————$100.00M
R&D expense$2.40M$9.51M$4.68M$9.97M$5.56M
SG&A expense$8.67M$7.17M$6.68M$7.61M$9.26M
Operating income-$11.08M-$16.68M-$12.85M-$52.16M-$15.59M
Pretax income-$9.49M-$12.77M-$14.69M-$51.97M-$10.47M
Income tax-$1.70M-$3.20M-$1.83M-$9.54M-$648,000
Net income-$7.79M-$9.57M-$12.85M-$42.43M-$9.82M
EBITDA-$11.07M-$16.67M-$12.84M-$52.03M-$15.59M
EPS (basic)-0.47-0.79-1.35-5.71-0.27
EPS (diluted)-0.47-0.79-1.35-5.71-0.27
Weighted avg. shares (diluted)16.51M12.09M9.53M7.44M36.84M
Balance sheet
Cash & equivalents$16.98M$22.13M$23.00M$27.88M$30.34M
Short-term investments——$0$15,000$13.32M
Receivables——$722,000$802,000$548,000
Current assets$17.38M$22.71M$24.01M$29.29M$45.28M
PP&E, net$8,000$15,000$24,000$104,000$20.89M
Goodwill$8.14M$8.14M$8.14M$8.14M$12.96M
Intangibles$41.13M$41.13M$41.13M$41.13M$69.81M
Total assets$66.65M$71.99M$73.30M$79.12M$128.62M
Current liabilities$2.15M$1.93M$1.68M$3.41M$3.26M
Total liabilities$2.76M$5.38M$11.56M$11.17M$20.35M
Shareholders' equity$63.90M$66.61M$61.74M$67.95M$108.27M
Shares outstanding16.02M13.72M9.40M7.44M44.29M
Cash flow statement
Operating cash flow-$8.87M-$14.90M-$12.33M-$15.91M-$17.23M
Investing cash flow$0$0$104,000$13.15M-$3.52M
Financing cash flow$3.71M$14.03M$7.36M$304,000$0
Depreciation & amortization$7,000$7,000$11,000$124,000$0
Stock-based compensation$798,000$730,000$913,000$1.81M$1.34M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.